TTD can be an overestimate compared with PFS (approximately 2 mo more in pooled EGFR-mutant lung cancer studies), but it also may reflect a more real-world approach where TKI is often continued in the presence of clinical benefit despite potential Response Evaluation Criteria in Solid Tumors progression.31 The gene discussed is EGFR; the disease is lung cancer.